Type 2 diabetes mellitus (T2DM) is a complex disease in which both genetic and
environmental factors interact in determining impaired β-cell insulin secretion and peripheral …

Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global
epidemic. In order to achieve optimal glucose control, it is often necessary to rely on …

This paper presents the eleventh update of the human obesity gene map, which
incorporates published results up to the end of October 2004. Evidence from single‐gene …

Background/aims The aim of this study was to assess the effect of functional ENPP1
(ectoenzyme nucleotide pyrophosphate phosphodiesterase 1)/PC-1 (plasma cell antigen-1) …

Diabetes mellitus affects approximately 382 million individuals worldwide and is a leading
cause of morbidity and mortality. Over 40 and nearly 80 genetic loci influencing susceptibility …

Pharmacogenetics provides opportunities for informed decision-making along the
pharmaceutical pipeline. There is a growing literature of retrospective studies of marketed …

With rapidly increasing prevalence, diabetes has become one of the major causes of
mortality worldwide. According to the latest studies, genetic information makes substantial …

Type 2 diabetes mellitus (T2D) is a chronic metabolic disease resulting from insulin
resistance and progressively reduced insulin secretion, which leads to impaired glucose …

The sulfonylureas stimulate insulin release from pancreatic β cells, and have been a
cornerstone of Type 2 diabetes pharmacotherapy for over 50 years. Although sulfonylureas …

A variety of treatment modalities exist for individuals with type 2 diabetes mellitus (T2D). In
addition to dietary and physical activity interventions, T2D is also treated pharmacologically …